Analystreport

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $4.00 to $3.50. They now have a "neutral" rating on the stock.

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com